ConcertAI and Caris Life Sciences Partner with AbbVie to Fast-Track Oncology Pipeline and Clinical Trials

Written By Kathleen Otto

ConcertAI and Caris Life Sciences announce a multi-year partnership to bolster AbbVie's precision medicine-driven research and development in oncology, utilizing Caris' extensive real-world oncology database and ConcertAI's research-grade clinical data. The collaboration aims to guide the development of targeted therapies for optimal patient outcomes and leverage AI/ML for streamlined oncology clinical trials and enhanced patient enrollment

Kathleen Otto
Previous

Island Pharmaceuticals Repurposes Drug to Tackle Mosquito-Borne Diseases Globally
Next

Arlington Economic Development Corporation Amplifies Outreach to Attract Businesses and Developers